Sulfone and sulfoxide-containing pharmaceuticals: targets, pharmacological properties and SAR studies

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
MedChemComm Pub Date : 2026-04-28 DOI:10.1039/D5MD01089F
Yiran Zhou, Jinqu Li, Yiou Mei, Yuzhu Chen, Fengxia Sun and Yunfei Du
{"title":"Sulfone and sulfoxide-containing pharmaceuticals: targets, pharmacological properties and SAR studies","authors":"Yiran Zhou, Jinqu Li, Yiou Mei, Yuzhu Chen, Fengxia Sun and Yunfei Du","doi":"10.1039/D5MD01089F","DOIUrl":null,"url":null,"abstract":"<p >Sulfone/sulfoxide functional groups are extremely important functional groups widely utilized in the design of biologically active drugs. Pharmaceuticals incorporating sulfone/sulfoxide have shown a broad spectrum of pharmacological properties, including anti-inflammatory, antimicrobial, anticancer activities, <em>etc.</em> They have also exhibited excellent metabolic stability and pharmacokinetic properties. Over the past decades, regulatory agencies, including the FDA, have approved numerous drugs featuring these functional groups for treating various clinical conditions, and the incorporation of sulfone/sulfoxide groups continues to attract significant attention from medicinal chemists. This review aims to provide a comprehensive overview of 33 approved drugs containing sulfone/sulfoxide moieties, focusing on their targets, pharmacokinetic properties, and structure–activity relationship studies. Specifically, the SAR is validated by comparing the biological activity and pharmacokinetics of each drug with its structurally analogous compounds lacking sulfone/sulfoxide groups, offering actionable evidence for the functional roles of these moieties.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 6","pages":" 2743-2767"},"PeriodicalIF":3.5970,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2026/md/d5md01089f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Sulfone/sulfoxide functional groups are extremely important functional groups widely utilized in the design of biologically active drugs. Pharmaceuticals incorporating sulfone/sulfoxide have shown a broad spectrum of pharmacological properties, including anti-inflammatory, antimicrobial, anticancer activities, etc. They have also exhibited excellent metabolic stability and pharmacokinetic properties. Over the past decades, regulatory agencies, including the FDA, have approved numerous drugs featuring these functional groups for treating various clinical conditions, and the incorporation of sulfone/sulfoxide groups continues to attract significant attention from medicinal chemists. This review aims to provide a comprehensive overview of 33 approved drugs containing sulfone/sulfoxide moieties, focusing on their targets, pharmacokinetic properties, and structure–activity relationship studies. Specifically, the SAR is validated by comparing the biological activity and pharmacokinetics of each drug with its structurally analogous compounds lacking sulfone/sulfoxide groups, offering actionable evidence for the functional roles of these moieties.

Abstract Image

含砜和亚砜的药物:靶点、药理学性质和SAR研究。
砜/亚砜官能团是生物活性药物设计中广泛应用的重要官能团。含有砜/亚砜的药物具有广泛的药理特性,包括抗炎、抗菌、抗癌活性等。它们还表现出良好的代谢稳定性和药代动力学特性。在过去的几十年里,包括FDA在内的监管机构已经批准了许多具有这些功能基团的药物用于治疗各种临床疾病,并且砜/亚砜基团的结合继续吸引着药物化学家的极大关注。本文综述了33种已获批准的含有砜/亚砜基团的药物,重点介绍了它们的靶点、药代动力学特性和构效关系研究。具体来说,通过将每种药物的生物活性和药代动力学与缺乏砜/亚砜基团的结构类似的化合物进行比较,验证了SAR,为这些部分的功能作用提供了可行的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书